Lilly's Zepbound tops Wegovy for weight loss

Zepbound leads to more weight loss than Wegovy, new study finds
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.
Eli Lilly's Zepbound Beats Novo Nordisk's Wegovy In Head-To-Head Weight-Loss Trial
Eli Lilly said Wednesday that its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in a head-to-head clinical trial.
Eli Lilly’s Zepbound Beats Novo Nordisk’s Wegovy in First Head-to-Head Study
People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s drug.
Eli Lilly’s Weight-Loss Drug Zepbound More Effective than Novo’s Wegovy, Study Shows
Eli Lilly’s obesity drug Zepbound is more effective than rival Novo Nordisk’s drug Wegovy, a head-to-head trial showed, Lilly said in a statement Wednesday.On average, Zepbound led to a superior weight loss of 20.
Lilly's Zepbound tops Wegovy for weight loss in head-to-head trial
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines.
Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound® (tirzepatide) provided a 47% greater relative weight loss compared to Wegovy® (semaglutide).
Weight loss drug battle heats up as Wegovy beaten in head-to-head trial
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines.
Trial shows Lilly’s Zepbound helps patients lose far more weight than competing drug
Eli Lilly and Co. said its weight-loss treatment Zepbound helped patients lose 47% more relative weight than competitor Novo Nordisk’s obesity treatment Wegovy in a head-to-head clinical trial.
Eli Lilly stock higher following surprise weight loss treatment data
Analysts see the market for GLP-1 weight loss treatments rising to around $70 billion over the next five years.
Why your co-pay for weight loss drugs like Wegovy just went through the roof
Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.
Lilly’s Zepbound Beats Novo’s Wegovy in First Head-to-Head Trial
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head trial of the two blockbusters.
The Financial Express21m
Lilly’s Zepbound outshines Wegovy in weight loss head-to-head trial
Wegovy was approved in the US as a treatment for heart disease in March, while Zepbound is expected to be given the green ...
BioPharma Dive1d
Diabetes advocacy group discourages use of compounded GLP-1 drugs
The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...
Dr. Roach: In two cases, Zepbound provides great benefit to overall health
Dear S.R.: Tirzepatide (Zepbound), like semaglutide, is a prescription medication originally used for diabetes but now ...
Weight-loss drugs deliver life-changing health benefits - and big profits
State measures now seek to remove barriers to weight-loss drugs, as demand for the meds skyrockets amid rising concerns about ...
A Thumb on the Scale for Wegovy
Biden’s Center for Medicare and Medicaid Services extends coverage by making nonsense of the law.
Eli Lilly’s Growth Driven by Strong Prescription Trends for Mounjaro and Zepbound
Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and increased the price target ...
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?
The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...
HealthDay on MSN6d
Zepbound Slashes Diabetes Risk in Obese Users
The cutting-edge weight-loss drug Zepbound can protect obese people from developing type 2 diabetes, a new clinical trial has ...